Dr. Meiyu Geng is currently a professor and Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Dr. Geng has played a leading role in the development of the first-in-class anti-AD treatment GV-971, conditional approved in China in 2019 and got formal approval in 2020 from the US Food and Drug Administration (FDA) for its international multi-center Phase III clinical study in the U.S. Her research area also includes the discovery and development of molecularly targeted cancer therapies. Dr. Geng led the development of over ten targeted therapies in the area of receptor tyrosine kinases and epigenetics, including 8 in clinical trial in China. In parallel to anticancer drug discovery, her team is engaged in biomarker discovery to guide personalized cancer therapy and mechanism-based combination therapies. Dr. Geng received her Ph.D. degree from Tokyo University, Japan. Dr. Geng has published more than 240 research articles in peer-review journals including Cell, Cancer Cell, Cell Res, J Natl Cancer Inst, Hepatology, Nat Commun, Cancer Res etc. She is the co-inventor of more than 200 domestic or international patents. Dr. Geng is the recipient of a number of prestigious national awards including “National Award for Technological Invention”, “Outstanding Academic Leader of Shanghai”, China Guanghua Engineering Science and Technology Award and WuJieping-Paul Janssen Medical & Pharmaceutical Award. She is recognized as an expert with significant contributions by the Chinese Academy of Sciences.